ArticlePloS one2025
Association between non-invasive biomarkers and quality of life in Primary Sclerosing Cholangitis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsPrimary sclerosing cholangitis (PSC) is a rare chronic liver disease that impact quality of life (QoL). This study investigated the association between biomarkers of PSC disease severity and QoL.
methodsProspective study involving 80 participants with PSC at baseline and 55 at 1-year follow-up. QoL was assessed using patient reported outcomes (PROMs): RAND-SF36, SF6D and PSC-PRO. MRI-MRCP data was analysed using LiverMultiscan for iron-corrected liver T1 (cT1) and MRCP+ for the relative severity of intrahepatic biliary dilatations (RSIBD). Disease severity was also classified using FibroScan liver stiffness (LS), enhanced liver fibrosis (ELF), Mayo risk score (MRS), Amsterdam-Oxford model (AOM), alkaline phosphatase (ALP), presence of extrahepatic disease and dominant stricture (DS). Descriptive and regression analyses were conducted.
resultsAt baseline, more advanced PSC was associated with differences in PROMs, AOM > 2, (PSC-PRO PSC symptoms, 5.181, p = 0.048), LS > 9.6 kPa (SF-6D, -0.081, p = 0.027), cT1 > 825ms (SF6D QoL, -0.161, p = 0.004; SF36 PCS, -10.595, p = 0.001; SF36 MCS, -10.726, p = 0.012), DS (PSC-PRO symptoms scores, 5.800, p = 0.025), RSIBD (SF-6D, -0.081, p = 0.016). During follow-up, increase in LS was associated with a reduction in QoL measured via SF-6D (-0.002, p < 0.001), SF36 physical component summary (-0.246, p < 0.001) and SF36 mental component summary (-0.171, p < 0.001).
conclusionsQoL in PSC was associated with biomarkers of parenchymal liver fibrosis (LS, cT1), biliary disease (dominant strictures, RSIBD), and composite scores of disease severity (AOM). Increasing LS predicted further declines in QoL. Further research should explore MRCP+ metrics and their impact on QoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.